1-(7-chloro-4-methylquinazolin-2-yl)-3-(3-(dimethylamino)phenyl)guanidine

ID: ALA5220879

PubChem CID: 168298530

Max Phase: Preclinical

Molecular Formula: C18H19ClN6

Molecular Weight: 354.85

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1nc(NC(=N)Nc2cccc(N(C)C)c2)nc2cc(Cl)ccc12

Standard InChI:  InChI=1S/C18H19ClN6/c1-11-15-8-7-12(19)9-16(15)23-18(21-11)24-17(20)22-13-5-4-6-14(10-13)25(2)3/h4-10H,1-3H3,(H3,20,21,22,23,24)

Standard InChI Key:  JKMSDBVMGKHNMW-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
   -3.9293    0.4107    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2147    0.8230    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5028    0.4111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5028   -0.4140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2129   -0.8258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9293   -0.4177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6439   -0.8303    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   -1.7851   -0.8281    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0734   -0.4115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0752    0.4094    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7901    0.8219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7901    1.6471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3587   -0.8241    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3558   -0.4115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0704   -0.8241    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7851   -0.4115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3558    0.4136    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7853    0.4137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4982    0.8244    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2130    0.4117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2146   -0.4093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5028   -0.8258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9292   -0.8219    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6439   -0.4093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9292   -1.6471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  6  7  1  0
  4  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
  3 11  1  0
 11 12  1  0
  9 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
 14 17  2  0
 18 16  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 22 21  2  0
 16 22  1  0
 21 23  1  0
 23 24  1  0
 23 25  1  0
M  END

Alternative Forms

  1. Parent:

    ALA5220879

    ---

Associated Targets(Human)

Premature termination codon (106 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 354.85Molecular Weight (Monoisotopic): 354.1360AlogP: 4.12#Rotatable Bonds: 3
Polar Surface Area: 76.93Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 5.84CX LogP: 4.11CX LogD: 4.09
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.49Np Likeness Score: -1.60

References

1. Morrill C, Friesen WJ, Babu S, Baiazitov RY, Du W, Karloff DB, Lee CS, Moon YC, Ren H, Sierra J, Tomizawa Y, Vazirani P, Welch EM, Xue X, Zhuo J..  (2022)  Guanidino quinazolines and pyrimidines promote readthrough of premature termination codons in cells with native nonsense mutations.,  76  [PMID:36150638] [10.1016/j.bmcl.2022.128989]

Source